Werner Streif

TL;DR: Disturbance of fibrinogen/fibrin polymerization is the primary problem triggering dilutional coagulopathy during major orthopedic surgery, and these undesirable effects of intravascular volume therapy can be reversed by increasing fibrInogen concentration by administering fibr inogen concentrate, even during continuing blood loss and intrav vascular volume replacement.

TL;DR: Replacing 65% of the estimated blood volume with gelatin in swine resulted in dilutional coagulopathy; subsequent fibrinogen administration improved clot formation and reduced blood loss significantly.

TL;DR: These data show for the first time that impaired clot formation during thrombocytopenia improves with administration of fibrinogen concentrate, which results in a slowdown of blood loss and prolonged survival.

TL;DR: In an in vitro model, whether the addition of fibrinogen to diluted blood samples can reverse dilutional coagulopathy is investigated, and clotting times decreased and clot firmness, as well asfibrin polymerization, increased in all dilute blood samples.

TL;DR: Treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased bleeding, as compared with standard anticoagulants in children with acute venous thromboembolism.